Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX + Pembrolizumab in MMR-p Advanced Colorectal Cancer
NCT02981524Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GVAX pancreatic cancer vaccine and pembrolizumab in colorectal cancer (metastatic) (mCRC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 1 year. Started May 2017; status: completed.
02
Drugs
GVAX pancreatic cancer vaccinepembrolizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02981524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981524.